A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain
Phase of Trial: Phase IV
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Duloxetine (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 06 Jun 2017 Status changed from recruiting to completed.
- 19 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 May 2017.
- 19 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 May 2017.